Cryosurgery Devices Market By Product Type (Cryoprobes, Localized Cryosurgical Units, Cryoguns, Gas Cylinders, Cryotherapy Chambers); By Application (Oncology, Dermatology, Cardiology, Pain Management, Gynecology, Others); By End User (Hospitals, Ambulatory Surgical Centers, Dermatology & Cosmetic Clinics, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cryosurgery Devices Market Size, Share, Growth & Forecast 2026–2032

The Global Cryosurgery Devices Market will witness a robust CAGR of 9.8%, valued at USD 3.2 billion in 2025, expected to appreciate and reach USD 5.6 billion by 2032.

 

FDA-approved cryosurgery devices include handheld dermatology tools and advanced tumor ablation systems.

 

Key cleared platforms include IceCure’s ProSense® and XSense® for liquid-nitrogen cryoablation in breast cancer, soft tissue, and other tumors. CSA Medical’s CryoSpray system is used for respiratory and GI tissue ablation. Brymill’s Cry-Ac devices and CryoConcepts systems are widely used in dermatology for skin lesions.

 

Development is focused on expanding cancer uses (kidney, lung, broader breast cancer) and improving smaller, single-probe cryoablation devices.

 

What Is Driving Growth in the Cryosurgery Devices Market?

The market is becoming more procedure-driven. Hospitals and clinics periodically purchase reusable consoles, cryosprayers, and localized systems, but every intervention can create demand for disposable probes, needles, catheters, gases, and accessories. Boston Scientific's ICEfx system, for instance, can support up to eight cryoablation needles, showing how one installed console can generate recurring disposable consumption across repeated procedures.

Hospital utilization confirms an established interventional base. CMS CY2024 OPPS rate-setting data included approximately 2,843 percutaneous renal cryoablation services, 254 pulmonary cryoablation services, 192 percutaneous liver cryoablation services, and four laparoscopic liver cryosurgery services. Renal cryoablation is the most visible of these publicly identifiable oncology procedures.

Dermatology adds a high-volume outpatient demand pool. More than 40 million Americans develop actinic keratoses annually, while approximately 3.3 million people develop an estimated 5.4 million basal and squamous cell skin cancers each year. These lesion volumes support recurring use of cryoguns, liquid nitrogen, accessories, tips, and other office-based cryosurgery products.

 

Which Product Type Leads the Cryosurgery Devices Market?

Cryoprobes

Cryoprobes led the product market with an estimated 34.0% share in 2025, equal to about USD 1.09 billion, and are projected to grow at a CAGR of 11.5% through 2032. Their position reflects direct use in tumor ablation, breast cryoablation, surgical procedures, and peripheral-nerve treatment. Because many probes are procedure-linked consumables, rising utilization can translate directly into recurring sales. Companies such as Boston Scientific, IceCure Medical, and AtriCure are active across oncology, breast, surgical, and pain-management cryo applications.

Localized Cryosurgical Units

Localized cryosurgical units accounted for an estimated 27.0% share, or USD 0.86 billion, in 2025 and are forecast to grow at a CAGR of 10.4%. Demand is increasing as hospitals and specialty centers expand focal-ablation capability and pair reusable systems with recurring probe or needle purchases. Platforms such as Boston Scientific ICEfx and IceCure ProSense illustrate this equipment-plus-consumables model.

Cryoguns

Cryoguns represented an estimated 18.0% share and USD 0.58 billion in 2025, with a projected CAGR of 8.4%. Demand is concentrated in dermatology and other outpatient settings where physicians treat superficial lesions. Providers such as Brymill Cryogenic Systems and Cortex Technology supply handheld liquid-nitrogen cryosurgical equipment, while longer equipment replacement cycles keep growth below procedure-linked cryoprobes.

Gas Cylinders

Gas cylinders held an estimated 12.0% share, equivalent to USD 0.38 billion in 2025, and are projected to grow at a CAGR of 7.1%. Their revenue follows utilization of liquid-nitrogen, nitrous-oxide, and other gas-based cryosurgical systems. Growth is comparatively moderate as alternative technologies reduce dependence on medical gases in selected treatment areas.

Cryotherapy Chambers

Cryotherapy chambers accounted for an estimated 9.0% share and USD 0.29 billion in 2025 and are projected to grow at a CAGR of 9.2%. Demand is concentrated in specialty therapeutic, rehabilitation, sports-medicine, and supervised-care settings. Unlike disposable probe categories, chamber revenue depends more heavily on facility investment and equipment replacement.

 

Which Applications Generate the Most Cryosurgery Device Demand?

Oncology

Oncology was the largest application in 2025, with an estimated 31.0% share and USD 0.99 billion in revenue, and is projected to grow at a CAGR of 11.2%. Cryoablation is used in selected kidney, prostate, lung, liver, bone, and breast tumors. U.S. cancer incidence in 2026 is projected at 333,830 prostate, 229,410 lung and bronchus, 80,450 kidney and renal-pelvis, and 42,340 liver and intrahepatic bile-duct cases. Growth comes from patients suitable for focal treatment and from recurring probes and needles consumed in image-guided procedures.

Dermatology

Dermatology accounted for an estimated 24.0% share and USD 0.77 billion in 2025 and is forecast to grow at a CAGR of 8.3%. Actinic keratoses, warts, and selected superficial skin cancers support a large routine procedure base. Companies such as Brymill and Cortex Technology serve this decentralized outpatient segment, where purchasing centers on handheld systems, cryogen, accessories, and replacement components.

Cardiology

Cardiology represented an estimated 18.0% share, or USD 0.58 billion, in 2025 and is projected to grow at a CAGR of 8.8%. Medtronic reports that more than 1.4 million patients worldwide have been treated cumulatively with its cryoballoon technology, demonstrating large-scale clinical use. Growth is becoming more competitive as pulsed-field ablation attracts electrophysiology investment, making future cryoballoon revenue increasingly dependent on its position within the broader AF ablation market.

Pain Management

Pain management held an estimated 12.0% share and USD 0.38 billion in 2025 and is projected to be the fastest-growing application at a CAGR of 12.5%. Peripheral-nerve cryoablation is expanding around postoperative pain management, while selected painful bone metastases provide another interventional use. AtriCure identified cryoSPHERE MAX probe sales for postoperative pain management as one contributor to U.S. growth in Q2 2026.

Gynecology

Gynecology represented an estimated 9.0% share and USD 0.29 billion in 2025, with a projected CAGR of 8.5%. Cervical precancer remains the primary cryotherapy demand pool. Screening and treatment programs expand the number of women reaching ablative treatment, while thermal ablation increasingly competes with conventional cryotherapy where medical-gas availability and treatment cost influence purchasing.

Others

Other applications accounted for an estimated 6.0% share and USD 0.19 billion in 2025 and are projected to grow at a CAGR of 8.0%. The segment covers smaller surgical, research, benign-lesion, and specialty therapeutic uses that generate additional demand without individually reaching the scale of oncology, dermatology, or cardiology.

 

Which End User Accounts for the Largest Market Share?

Hospitals

Hospitals led the Cryosurgery Devices Market with an estimated 51.0% share in 2025, representing USD 1.63 billion, and are projected to grow at a CAGR of 10.4%. Hospitals concentrate interventional oncology, electrophysiology, complex surgical cryoablation, and postoperative-pain procedures. This creates the broadest requirement for capital systems, image-guided procedures, and recurring disposable probes, needles, and catheters.

Ambulatory Surgical Centers

Ambulatory Surgical Centers accounted for an estimated 22.0% share and USD 0.70 billion in 2025 and are forecast to grow at the fastest end-user CAGR of 11.0%. The growth outlook reflects their expanding commercial role in suitable minimally invasive procedures where outpatient treatment can reduce dependence on inpatient capacity. Cryosurgical products suited to localized interventions can benefit as procedure volume develops in these settings.

Dermatology & Cosmetic Clinics

Dermatology & Cosmetic Clinics represented an estimated 20.0% share and USD 0.64 billion in 2025 and are expected to grow at a CAGR of 8.2%. Large volumes of superficial lesions support repeat procedures, while purchasing is distributed across physician practices rather than concentrated in major hospital systems. Cryoguns, applicators, gases, tips, and related accessories form the principal purchasing categories.

Academic & Research Institutions

Academic & Research Institutions held an estimated 7.0% share and USD 0.22 billion in 2025 and are projected to grow at a CAGR of 7.6%. Demand comes from clinical studies, evaluation of new indications, specialist training, and early adoption of focal-ablation approaches, including emerging breast and oncology applications.

 

Which Region Leads the Cryosurgery Devices Market?

North America

North America led with an estimated 42.0% share in 2025, representing USD 1.34 billion, and is projected to grow at a CAGR of 9.3%. High dermatology procedure volumes, established electrophysiology and interventional-radiology networks, cancer treatment capacity, and early commercialization of new indications support regional demand. IceCure reported 19 active U.S. accounts by the end of Q1 2026 following FDA authorization of ProSense for a defined low-risk breast-cancer population.

Europe

Europe accounted for an estimated 28.0% share and USD 0.90 billion in 2025 and is forecast to grow at a CAGR of 8.6%. Established hospital networks support cardiac, oncology, dermatology, and surgical cryo procedures. Rising PFA competition is changing the cardiac opportunity, increasing the importance of focal oncology and other specialist applications for future cryosurgery revenue.

Asia-Pacific

Asia-Pacific represented an estimated 21.0% share and USD 0.67 billion in 2025 and is projected to record the fastest regional CAGR of 12.2%. Cancer-care investment, private hospital expansion, specialist interventional services, and broader access to minimally invasive treatment are enlarging the addressable procedure base. Cervical treatment programs also create ablative-device demand, although thermal ablation competes with conventional cryotherapy in cost-sensitive settings.

Latin America

Latin America held an estimated 5.0% share and USD 0.16 billion in 2025 and is projected to grow at a CAGR of 10.1%. Growth is concentrated around private hospitals, oncology centers, and urban specialist facilities adding image-guided and minimally invasive treatment capacity.

Middle East & Africa

The Middle East & Africa accounted for an estimated 4.0% share and USD 0.13 billion in 2025 and are projected to grow at a CAGR of 9.8%. Gulf healthcare investment supports advanced hospital-based cryoablation, while cervical precancer programs and lower-cost outpatient treatment create a different demand profile across African markets.

 

What Recent Developments Are Expanding the Cryosurgery Devices Market?

Breast cryoablation is one of the most important recent additions to the U.S. market. On October 3, 2025, the FDA granted De Novo authorization for IceCure Medical's ProSense Cryoablation System for local treatment of a defined group of women aged 70 and older with low-risk breast cancer. IceCure subsequently reported 19 active U.S. accounts at the end of Q1 2026, up from 13 before authorization, and plans a 30-site U.S. ChoICE post-market study. The commercial model combines system placement with recurring disposable-probe consumption.

Postoperative pain is expanding through a different revenue pathway. AtriCure's cryoICE, cryoSPHERE, and cryoXT probes support temporary peripheral-nerve ablation in surgical settings. AtriCure reported Q2 2026 worldwide revenue of USD 153.6 million, up 12.8% year over year, and identified cryoSPHERE MAX as one contributor to U.S. revenue growth.

Cardiac cryoablation remains commercially significant but is entering a technology transition. The established cryoballoon base and more than 1.4 million cumulative Medtronic-treated patients support continued procedure demand, while PFA is attracting new electrophysiology investment. This shifts incremental market opportunity toward a broader mix of oncology, pain management, breast cryoablation, and other focal procedures.

 

Who Are the Key Companies in the Cryosurgery Devices Market?

Boston Scientific – Interventional Oncology: Boston Scientific competes through the ICEfx Cryoablation System and associated cryoablation needles. Its combination of installed systems and recurring disposable use gives the company direct exposure to increasing image-guided oncology procedures.

 

Medtronic – Cardiac Cryoablation: Medtronic has substantial cardiac cryoablation scale through Arctic Front cryoballoon technology, with more than 1.4 million cumulative patients treated worldwide. Its competitive position increasingly reflects the coexistence of established cryoablation and newer cardiac-ablation technologies.

 

AtriCure – Surgical Cryo and Pain Management: AtriCure has built a differentiated position around surgical cryoablation and postoperative pain management. Increased use of cryoSPHERE expands recurring probe demand beyond conventional tumor and cardiac ablation.

 

IceCure Medical – Breast Cryoablation: IceCure is developing a new U.S. commercial pathway following FDA authorization of ProSense. Growth in active customer accounts and post-market clinical activity can increase both system utilization and disposable-probe demand.

 

CooperSurgical, Brymill Cryogenic Systems, and Cortex Technology – Specialty Cryotherapy: These companies serve cervical and dermatologic cryotherapy markets where demand is driven by physician-office procedures, equipment replacement, cryogen, and accessories.

 

Across the Cryosurgery Devices Market, the strongest revenue opportunity is shifting toward repeat procedure consumption around installed platforms. Cryoprobes lead the product segment, oncology generates the largest application revenue, hospitals remain the largest end-user group, and Asia-Pacific offers the fastest regional growth outlook as specialist treatment capacity expands.

 

Cryosurgery Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.2 Billion
Revenue Forecast in 2032	USD 5.6 Billion
Overall Growth Rate	CAGR of 9.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Cryoprobes, Localized Cryosurgical Units, Cryoguns, Gas Cylinders, Cryotherapy Chambers
By Application	Oncology, Dermatology, Cardiology, Pain Management, Gynecology, Others
By End User	Hospitals, Ambulatory Surgical Centers, Dermatology & Cosmetic Clinics, Academic & Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of minimally invasive cryoablation across oncology and pain-management procedures; recurring demand for disposable cryoprobes, needles, catheters, gases, and accessories; high outpatient treatment volumes in dermatology; widening regulatory acceptance and clinical use of focal cryoablation systems
Customization Option	Available upon request